HRP20190250T1 - Pripravci koji sadrže ublaženi virus newcastleske bolesti i postupci uporabe za liječenje neoplazije - Google Patents
Pripravci koji sadrže ublaženi virus newcastleske bolesti i postupci uporabe za liječenje neoplazije Download PDFInfo
- Publication number
- HRP20190250T1 HRP20190250T1 HRP20190250TT HRP20190250T HRP20190250T1 HR P20190250 T1 HRP20190250 T1 HR P20190250T1 HR P20190250T T HRP20190250T T HR P20190250TT HR P20190250 T HRP20190250 T HR P20190250T HR P20190250 T1 HRP20190250 T1 HR P20190250T1
- Authority
- HR
- Croatia
- Prior art keywords
- newcastle disease
- disease virus
- attenuated newcastle
- virus
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/17—Newcastle disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16141—Use of virus, viral particle or viral elements as a vector
- C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18141—Use of virus, viral particle or viral elements as a vector
- C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361873039P | 2013-09-03 | 2013-09-03 | |
| EP14761317.8A EP3041490B1 (en) | 2013-09-03 | 2014-09-02 | Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia |
| PCT/EP2014/068619 WO2015032755A1 (en) | 2013-09-03 | 2014-09-02 | Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190250T1 true HRP20190250T1 (hr) | 2019-05-31 |
Family
ID=51492938
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190250TT HRP20190250T1 (hr) | 2013-09-03 | 2014-09-02 | Pripravci koji sadrže ublaženi virus newcastleske bolesti i postupci uporabe za liječenje neoplazije |
| HRP20220653TT HRP20220653T1 (hr) | 2013-09-03 | 2014-09-02 | Sastavi koji sadrže oslabljeni virus newcastleske bolesti i postupci uporabe za liječenje neoplazije |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220653TT HRP20220653T1 (hr) | 2013-09-03 | 2014-09-02 | Sastavi koji sadrže oslabljeni virus newcastleske bolesti i postupci uporabe za liječenje neoplazije |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10519426B2 (enExample) |
| EP (3) | EP4101457A1 (enExample) |
| JP (2) | JP6557234B2 (enExample) |
| KR (2) | KR102285894B1 (enExample) |
| CN (2) | CN106163532B (enExample) |
| AU (2) | AU2014317215C1 (enExample) |
| CA (1) | CA2922071C (enExample) |
| CY (2) | CY1121993T1 (enExample) |
| DK (2) | DK3508209T3 (enExample) |
| EA (2) | EA039404B1 (enExample) |
| ES (2) | ES2708755T3 (enExample) |
| HK (2) | HK1231393A1 (enExample) |
| HR (2) | HRP20190250T1 (enExample) |
| HU (1) | HUE042382T2 (enExample) |
| LT (2) | LT3508209T (enExample) |
| ME (1) | ME03345B (enExample) |
| MX (2) | MX367768B (enExample) |
| PL (2) | PL3041490T3 (enExample) |
| PT (2) | PT3041490T (enExample) |
| RS (2) | RS58332B1 (enExample) |
| SI (2) | SI3508209T1 (enExample) |
| SM (2) | SMT202200214T1 (enExample) |
| TR (1) | TR201902073T4 (enExample) |
| TW (1) | TWI653334B (enExample) |
| WO (1) | WO2015032755A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5603012B2 (ja) | 2005-12-02 | 2014-10-08 | トヘ モウント シナイ スクール オフ メディシネ オフ ニューヨーク ウニベルシトイ | 非天然表面タンパク質を提示するキメラウイルス及びその使用 |
| EP2393921B1 (en) | 2009-02-05 | 2015-07-15 | Icahn School of Medicine at Mount Sinai | Chimeric newcastle disease viruses and uses thereof |
| PE20151921A1 (es) | 2013-03-14 | 2015-12-26 | Icahn School Med Mount Sinai | Virus de la enfermedad de newcastle y usos de los mismos |
| PL3041490T3 (pl) * | 2013-09-03 | 2019-05-31 | Medimmune Ltd | Kompozycje zawierające atenuowany wirus choroby Newcastle i sposoby ich stosowania w leczeniu neoplazji |
| AU2015222685A1 (en) | 2014-02-27 | 2016-09-08 | Viralytics Limited | Combination method for treatment of cancer |
| WO2016176510A1 (en) * | 2015-04-28 | 2016-11-03 | University Of Georgia Research Foundation, Inc. | Piv5-based amplifying virus-like particles |
| EP3400291B2 (en) | 2016-01-08 | 2024-02-28 | Replimune Limited | Engineered virus |
| EP3246410A1 (en) * | 2016-05-19 | 2017-11-22 | Klinikum rechts der Isar der Technischen Universität München | Vsv/ndv hybrid viruses for oncolytic therapy of cancer |
| GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| KR101964610B1 (ko) * | 2017-03-13 | 2019-04-03 | 대한민국 | 신규한 종양용해성 바이러스 및 이의 용도 |
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| CN107254450A (zh) * | 2017-07-20 | 2017-10-17 | 扬州大学 | 克服鸡新城疫母源抗体影响的嵌合新城疫病毒疫苗载体候选株及构建方法 |
| CN108486279A (zh) * | 2017-09-21 | 2018-09-04 | 山东省农业科学院家禽研究所 | 一种基于荧光定量pcr技术检测鸽新城疫病毒的方法 |
| EP3552608A1 (en) * | 2018-04-09 | 2019-10-16 | Rapo Yerape B.H. Ltd | Increased activity of oncoloytic newcastle disease virus |
| CN112601547A (zh) | 2018-06-21 | 2021-04-02 | 雷普利穆内有限公司 | 使用溶瘤病毒的治疗 |
| CA3106170A1 (en) * | 2018-07-13 | 2020-01-16 | Icahn School Of Medicine At Mount Sinai | Apmv and uses thereof for the treatment of cancer |
| EP3837277A4 (en) | 2018-08-17 | 2022-05-11 | Icahn School of Medicine at Mount Sinai | RECOMBINANT NEWCASTLE DISEASE VIRUSES AND THEIR USES IN THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS INFECTION |
| CN110859968A (zh) * | 2019-11-21 | 2020-03-06 | 四川安可康生物医药有限公司 | 激活对肿瘤的系统免疫反应的基因生物药物 |
| US20240245805A1 (en) * | 2020-03-20 | 2024-07-25 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| WO2021229270A1 (es) | 2020-05-13 | 2021-11-18 | Laboratorio Avi-Mex, S.A. De C.V. | Vacuna recombinante contra covid-19 en vector viral |
| CN115197949A (zh) * | 2021-04-13 | 2022-10-18 | 江苏康缘瑞翱生物医药科技有限公司 | 一种重组新城疫病毒rNDV-OX40L、其基因组、制备方法及其用途 |
| KR20240001198A (ko) * | 2021-04-26 | 2024-01-03 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | Apmv hn 및 f 단백질을 발현하는 키메라 뉴캐슬병 바이러스 |
| CA3161532A1 (en) * | 2021-06-03 | 2022-12-03 | University Of Guelph | Engineered newcastle disease virus vector and uses thereof |
| CN121263205A (zh) * | 2023-02-06 | 2026-01-02 | 塞维卡有限责任公司 | 修饰的piv5疫苗载体：制造方法和用途 |
| WO2025116613A1 (ko) * | 2023-11-29 | 2025-06-05 | 주식회사 카브 | 재조합 뉴캣슬병 바이러스 벡터를 포함하는 암 치료용 약제학적 조성물 |
| CN120290572A (zh) * | 2025-04-09 | 2025-07-11 | 梅尔顿(深圳)生物医药技术有限公司 | 一种重组新城疫病毒及其制备方法和在抗肿瘤中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7724558B1 (en) * | 1999-03-19 | 2010-05-25 | Nec Corporation | Magnetic signal transmission line |
| CA2383276A1 (en) * | 1999-09-24 | 2001-03-29 | Mayo Foundation For Medical Education And Research | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
| KR100801180B1 (ko) * | 2006-09-26 | 2008-02-05 | 주식회사 고려비엔피 | 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신 |
| EP2085092A1 (en) * | 2008-01-29 | 2009-08-05 | Bayer Schering Pharma Aktiengesellschaft | Attenuated oncolytic paramyxoviruses encoding avian cytokines |
| US20090208495A1 (en) | 2008-02-14 | 2009-08-20 | Bayer Schering Pharma Ag | Anti-tumor effective paramyxovirus |
| EP2393921B1 (en) * | 2009-02-05 | 2015-07-15 | Icahn School of Medicine at Mount Sinai | Chimeric newcastle disease viruses and uses thereof |
| PE20151921A1 (es) * | 2013-03-14 | 2015-12-26 | Icahn School Med Mount Sinai | Virus de la enfermedad de newcastle y usos de los mismos |
| PL3041490T3 (pl) * | 2013-09-03 | 2019-05-31 | Medimmune Ltd | Kompozycje zawierające atenuowany wirus choroby Newcastle i sposoby ich stosowania w leczeniu neoplazji |
| CN109099045A (zh) * | 2018-10-30 | 2018-12-28 | 浙江斯泰新材料科技股份有限公司 | 防松锁固型螺钉 |
-
2014
- 2014-09-02 PL PL14761317T patent/PL3041490T3/pl unknown
- 2014-09-02 CA CA2922071A patent/CA2922071C/en active Active
- 2014-09-02 SM SM20220214T patent/SMT202200214T1/it unknown
- 2014-09-02 PT PT14761317T patent/PT3041490T/pt unknown
- 2014-09-02 ME MEP-2019-40A patent/ME03345B/me unknown
- 2014-09-02 DK DK18188565.8T patent/DK3508209T3/da active
- 2014-09-02 HU HUE14761317A patent/HUE042382T2/hu unknown
- 2014-09-02 TR TR2019/02073T patent/TR201902073T4/tr unknown
- 2014-09-02 EP EP22160157.8A patent/EP4101457A1/en not_active Withdrawn
- 2014-09-02 EA EA201690425A patent/EA039404B1/ru unknown
- 2014-09-02 JP JP2016537333A patent/JP6557234B2/ja not_active Expired - Fee Related
- 2014-09-02 ES ES14761317T patent/ES2708755T3/es active Active
- 2014-09-02 RS RS20190176A patent/RS58332B1/sr unknown
- 2014-09-02 DK DK14761317.8T patent/DK3041490T3/en active
- 2014-09-02 HR HRP20190250TT patent/HRP20190250T1/hr unknown
- 2014-09-02 ES ES18188565T patent/ES2914577T3/es active Active
- 2014-09-02 US US14/916,102 patent/US10519426B2/en active Active
- 2014-09-02 SI SI201431957T patent/SI3508209T1/sl unknown
- 2014-09-02 KR KR1020167008307A patent/KR102285894B1/ko not_active Expired - Fee Related
- 2014-09-02 RS RS20220481A patent/RS63291B1/sr unknown
- 2014-09-02 PT PT181885658T patent/PT3508209T/pt unknown
- 2014-09-02 HK HK17105137.4A patent/HK1231393A1/zh unknown
- 2014-09-02 CN CN201480048630.4A patent/CN106163532B/zh active Active
- 2014-09-02 KR KR1020217012332A patent/KR102310692B1/ko not_active Expired - Fee Related
- 2014-09-02 EP EP18188565.8A patent/EP3508209B1/en active Active
- 2014-09-02 AU AU2014317215A patent/AU2014317215C1/en not_active Ceased
- 2014-09-02 EP EP14761317.8A patent/EP3041490B1/en active Active
- 2014-09-02 SM SM20190094T patent/SMT201900094T1/it unknown
- 2014-09-02 MX MX2016002771A patent/MX367768B/es active IP Right Grant
- 2014-09-02 WO PCT/EP2014/068619 patent/WO2015032755A1/en not_active Ceased
- 2014-09-02 SI SI201431082T patent/SI3041490T1/sl unknown
- 2014-09-02 CN CN202010064863.0A patent/CN111944767A/zh active Pending
- 2014-09-02 HR HRP20220653TT patent/HRP20220653T1/hr unknown
- 2014-09-02 PL PL18188565T patent/PL3508209T3/pl unknown
- 2014-09-02 HK HK16114099.3A patent/HK1225643B/en not_active IP Right Cessation
- 2014-09-02 LT LTEP18188565.8T patent/LT3508209T/lt unknown
- 2014-09-02 EA EA202191926A patent/EA202191926A3/ru unknown
- 2014-09-02 LT LTEP14761317.8T patent/LT3041490T/lt unknown
- 2014-09-03 TW TW103130466A patent/TWI653334B/zh active
-
2016
- 2016-03-02 MX MX2019010364A patent/MX2019010364A/es unknown
-
2019
- 2019-02-08 CY CY20191100170T patent/CY1121993T1/el unknown
- 2019-06-24 AU AU2019204419A patent/AU2019204419B2/en not_active Ceased
- 2019-07-11 JP JP2019129161A patent/JP6862500B2/ja not_active Expired - Fee Related
- 2019-11-14 US US16/684,241 patent/US11471499B2/en active Active
-
2022
- 2022-05-25 CY CY20221100362T patent/CY1126790T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220653T1 (hr) | Sastavi koji sadrže oslabljeni virus newcastleske bolesti i postupci uporabe za liječenje neoplazije | |
| JP2019193662A5 (enExample) | ||
| TW201613956A (en) | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) | |
| JP2016533749A5 (enExample) | ||
| HRP20240078T1 (hr) | Imuno-onkolitičke terapije | |
| MX379423B (es) | Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales. | |
| PH12020500433A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| HRP20231025T1 (hr) | Onkolitički virus vakcinije | |
| SG10201804469RA (en) | Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods | |
| PH12017501344A1 (en) | Oral care compositions and methods of use | |
| MX2016001426A (es) | Inmunoterapia novedosa contra varios tumores, tales como cancer de pulmon, que incluye cancer de pulmon de celula no pequeña (nsclc). | |
| MX2018005462A (es) | Composiciones inmunogénicas de rsv quimérico y métodos de uso. | |
| WO2015048339A3 (en) | Compositions and formulations for non-human nutrition and methods of production and use thereof | |
| JP2016527920A5 (enExample) | ||
| MA39907A (fr) | Nouvelle immunothérapie contre plusieurs tumeurs, du sang, notamment la leucémie aiguë myéloïde (lam) | |
| MX363347B (es) | Sal de omecamtiv mecarbilo y proceso para preparar la sal. | |
| EA202191602A3 (ru) | Не содержащая сыворотки среда для культивирования клеток | |
| DK3981414T3 (da) | Lyofiliserede præparater med højt overfladeareal, der indeholder arsenik til oral indgivelse i patienter | |
| MX2016006189A (es) | Extracto de algas para su uso en calidad de agente inmunomodulador. | |
| EA201891471A1 (ru) | Композиции фосфорамидатных производных нуклеозидных лекарственных средств | |
| MX2015017852A (es) | Agente terapeutico que comprende el anticuerpo anti-epirregulina humanizado con ingrediente activo contra el carcinoma de pulmon de celulas no pequeñas excluyendo el adenocarcinoma. | |
| NZ752371A (en) | Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same | |
| MX2023001622A (es) | Celulas dendriticas optimamente activadas que inducen una respuesta inmunologica antitumoral mayor o mejorada. | |
| WO2014169882A3 (zh) | 具有抗肿瘤活性的苯并咪唑类化合物、制备方法及其应用 | |
| MX2018002633A (es) | Formulaciones de pirofosfato férrico solido soluble, kits y métodos de uso de las mismas. |